Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a.
HBs proteins
HBsAg
peginterferon alfa-2a
predictors of response
subviral particles
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
05
04
2019
revised:
30
10
2019
accepted:
01
11
2019
pubmed:
14
11
2019
medline:
22
6
2021
entrez:
14
11
2019
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) contains three viral surface proteins, large, middle and small hepatitis B surface protein (LHBs, MHBs, SHBs). Proportions of LHBs and MHBs are lower in patients with inactive vs active chronic infection. Interferon alfa may convert hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) to an inactive carrier state, but prediction of sustained response is unsatisfactory. The aim of this study was to test the hypothesis that quantification of MHBs and LHBs may allow for a better prognosis of therapeutic response than total hepatitis B surface antigen (HBsAg) concentration. Hepatitis B surface proteins were measured before and during peginterferon alfa-2a therapy in serum from 127 Asian patients with HBeAg-positive CHB. Sustained response was defined as HBeAg seroconversion 24 weeks post-treatment. Mean total HBs levels were significantly lower in responders vs nonresponders at all time points (P < .05) and decreased steadily during the initial 24 weeks treatment (by 1.16 vs 0.86 ng/mL in responders/nonresponders respectively) with unchanged relative proportions. Genotype B had a two-fold higher proportion of LHBs than genotype C (13% vs 6%). HBV DNA, HBeAg, HBsAg and HBs protein levels predicted response equally well but not optimally (area under the receiver operating characteristic curve values >0.70). Hepatitis B surface protein levels differ by HBV genotype. However, quantification of HBs proteins has no advantage over the already established HBsAg assays to predict response to peginterferon alfa-2a therapy in HBeAg-positive patients.
Sections du résumé
BACKGROUND & AIMS
Hepatitis B virus (HBV) contains three viral surface proteins, large, middle and small hepatitis B surface protein (LHBs, MHBs, SHBs). Proportions of LHBs and MHBs are lower in patients with inactive vs active chronic infection. Interferon alfa may convert hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) to an inactive carrier state, but prediction of sustained response is unsatisfactory. The aim of this study was to test the hypothesis that quantification of MHBs and LHBs may allow for a better prognosis of therapeutic response than total hepatitis B surface antigen (HBsAg) concentration.
METHODS
Hepatitis B surface proteins were measured before and during peginterferon alfa-2a therapy in serum from 127 Asian patients with HBeAg-positive CHB. Sustained response was defined as HBeAg seroconversion 24 weeks post-treatment.
RESULTS
Mean total HBs levels were significantly lower in responders vs nonresponders at all time points (P < .05) and decreased steadily during the initial 24 weeks treatment (by 1.16 vs 0.86 ng/mL in responders/nonresponders respectively) with unchanged relative proportions. Genotype B had a two-fold higher proportion of LHBs than genotype C (13% vs 6%). HBV DNA, HBeAg, HBsAg and HBs protein levels predicted response equally well but not optimally (area under the receiver operating characteristic curve values >0.70).
CONCLUSIONS
Hepatitis B surface protein levels differ by HBV genotype. However, quantification of HBs proteins has no advantage over the already established HBsAg assays to predict response to peginterferon alfa-2a therapy in HBeAg-positive patients.
Substances chimiques
Antiviral Agents
0
DNA, Viral
0
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Interferon-alpha
0
Membrane Proteins
0
Recombinant Proteins
0
Polyethylene Glycols
3WJQ0SDW1A
peginterferon alfa-2a
Q46947FE7K
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
324-332Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Sarin SK, Kumar M, Lau GK, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98.
Terrault NA, Bzowej NH, Chang K, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283.
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398.
Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol. 1984;52:396-402.
Glebe D, Bremer CM. The molecular virology of hepatitis B virus. Semin Liver Dis. 2013;33:103-112.
Gerlich WH. Medical virology of hepatitis B: How it began and where we are now. Virol J. 2013;10:239.
Bruss V, Ganem D. The role of envelope proteins in hepatitis B virus assembly. Proc Natl Acad Sci USA. 1991;88:1059-1063.
Deepen R, Heermann KH, Uy A, Thomssen R, Gerlich WH. Assay of preS epitopes and preS1 antibody in hepatitis B virus carriers and immune persons. Med Microbiol Immunol. 1990;179:49-60.
Stibbe W, Gerlich WH. Variable protein composition of hepatitis B surface antigen from different donors. Virology. 1982;123:436-442.
Pfefferkorn M, Böhm S, Schott T, et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut. 2018;67:2045-2053.
Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58:872-880.
Chan H-Y, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol. 2011;55:1121-1131.
Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398-411.
Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-2695.
Liaw Y-F, Jia J-D, Chan H, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54:1591-1599.
Germaschewski V, Murray K. Screening a monoclonal antibody with a fusion-phage display library shows a discontinuity in a linear epitope within PreS1 of hepatitis B virus. J Med Virol. 1995;45:300-305.
Heermann KH, Waldeck F, Gerlich WH. Interaction between native human serum and the preS2 domain of the hepatitis B surface antigen. In: Zuckermann AJ, ed. Viral hepatitis and liver diseases. New York, NY: A. Liss; 1988:697-700.
Madalinski K, Burczynska B, Heermann KH, Uy A, Gerlich WH. Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. Clin Exp Immunol. 1991;84:493-500.
Peiffer K-H, Kuhnhenn L, Jiang B, et al. Divergent preS sequences in virion-associated hepatitis B virus genomes and subviral HBV surface antigen particles from HBV e antigen-negative patients. J Infect Dis. 2018;218:114-123.
Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther. 2008;13:211-220.
Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015;5:a021436.
Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol. 1997;71:9392-9399.
Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother. 1998;42:3200-3208.
Chuaypen N, Sriprapun M, Praianantathavorn K, et al. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. J Med Virol. 2017;89:130-138.
Wang NY, Zhang D, Zhao W, Li BA, Lin CQ. Hepatitis B virus large surface protein in serum as a candidate biomarker for evaluating hepatitis B virus infection. Clin Biochem. 2011;44:1199-1204.
Zhu X, Gong Q, Yu D, et al. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B. J Clin Virol. 2013;57:318-322.
Quiroga JA, Mora I, Carreño V, Herrera MI, Porres JC, Gerlich WH. Inhibition of albumin binding to hepatitis B virions by monoclonal antibody to the preS2 domain of the viral envelope. Digestion. 1987;38:212-220.
Koshy R, Koch S, von Loringhoven AF, Kahmann R, Murray K, Hofschneider PH. Integration of hepatitis B virus DNA: evidence for integration in the single-stranded gap. Cell. 1983;34:215-223.